<DOC>
	<DOCNO>NCT00872534</DOCNO>
	<brief_summary>To determine gastrointestinal safety PL-2200 versus immediate-release aspirin assess endoscopic gastroduodenal mucosal injury approve daily cardiac-protective dos aspirin ( 325 mg ) normal healthy volunteer .</brief_summary>
	<brief_title>Endoscopic Evaluation Upper Gastrointestinal ( GI ) Mucosal Damage Induced PL-2200 Versus Aspirin Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<criteria>Subject ≥50 ≤75 year age . Subject healthy . Subject BMI 20 32 If female child bear potential , subject negative pregnancy test nursing . Subject abnormal screening/baseline laboratory parameter endoscopic observation deem clinically significant Investigator . Subject active Helicobacter pylorus infection . Subject prior GI ulcer , bleeding , obstruction perforation . Subject take aspirin aspirin contain product within last 4 week , nonaspirin NSAID product within 2 week . Subject take follow medication within 2 week prior enrollment : Any antiplatelet agent , anticoagulant selective serotonin reuptake inhibitor . Subject use investigational agent within past 30 day . Subject hypersensitivity contraindication aspirin , ibuprofen , NSAID .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>To evaluate acute gastrointestinal safety PL-2100 .</keyword>
</DOC>